[Treatment options in deep vein thrombosis].
In the event of a deep vein thrombosis, the major concern is to prevent the subsequent development of an embolism or a recurrence. The therapeutic time gap to the development of the full effect of the vitamin K antagonists is bridged in the initial acute treatment phase with low molecular weight heparin (LMWH) or fondaparinux. In patients in whom vitamin K antagonists are contraindicated, or in pregnancy, secondary prophylaxis is alternatively continued with dose-adjusted LMWH. Compression therapy serves merely to prevent a post-thrombotic syndrome.
Bauersachs
Rupert M
RM
Medizinische Klinik IV Max-Ratschow-Klinik für Angiologie Städtisches Klinikum Darmstadt. Rupert.Bauersachs@Klinikum-Darmstadt.de
D000553:Ambulatory Care; D000925:Anticoagulants / Q000008:administration & dosage*; D001458:Bandages; D003131:Combined Modality Therapy; D006801:Humans; D010343:Patient Admission; D010349:Patient Compliance; D055502:Secondary Prevention; D020246:Venous Thrombosis / Q000628:therapy*
D000925:Anticoagulants